Hikma Pharmaceuticals Plc Price Target Raised to GBX 1,610 at Jefferies Group (HIK)
Equities research analysts at Jefferies Group lifted their price objective on shares of Hikma Pharmaceuticals Plc (LON:HIK) from GBX 1,600 ($27.17) to GBX 1,610 ($27.34) in a research note issued to investors on Friday. The firm currently has a “hold” rating on the stock. Jefferies Group’s target price would suggest a potential downside of 8.52% from the company’s current price.
Shares of Hikma Pharmaceuticals Plc (LON:HIK) traded down 2.17% on Friday, hitting GBX 1760.00. The stock had a trading volume of 275,642 shares. Hikma Pharmaceuticals Plc has a 52-week low of GBX 1004.00 and a 52-week high of GBX 1835.00. The stock has a 50-day moving average of GBX 1725. and a 200-day moving average of GBX 1553.. The company’s market cap is £3.481 billion.
HIK has been the subject of a number of other recent research reports. Analysts at Goldman Sachs upgraded shares of Hikma Pharmaceuticals Plc to a “buy” rating in a research note on Friday, July 18th. They now have a GBX 2,250 ($38.21) price target on the stock, up previously from GBX 1,800 ($30.57). Separately, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Hikma Pharmaceuticals Plc in a research note on Tuesday, June 17th. They now have a GBX 1,400 ($23.77) price target on the stock. Finally, analysts at Barclays reiterated an “overweight” rating on shares of Hikma Pharmaceuticals Plc in a research note on Monday, June 9th. They now have a GBX 1,890 ($32.09) price target on the stock. Five investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Hikma Pharmaceuticals Plc presently has a consensus rating of “Hold” and an average price target of GBX 1,698.57 ($28.84).
Hikma Pharmaceuticals PLC is engaged in the development, manufacture and marketing of a range of generic and in-licensed pharmaceutical products in solid, semi-solid, liquid and injectable final dosage forms.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.